|
|
|
|
|
|
|
|
Journal for ImmunoTherapy of Cancer
Background
Immune based therapies for cancer are emerging as promising strategies to treat a
number of malignancies. A more thorough biomarker assessment of the patients may provide
insights into the variability in response to such immune therapies. In a Phase I/Ib
clinical trial with the survivin-targeting vaccine DPX-Survivac, we showed the induction
of robust immune responses in ovarian cancer patients. In this study, we investigated
the potential of proteomic and metabolomic analysis of plasma to identify surrogate
biomarkers for efficacy, recurrence and adverse events (AE) in vaccine recipients.....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.